Date Approved


Degree Type

Open Access Thesis

Degree Name

Master of Science (MS)

Department or School


Committee Member

Andrei Kornilov, PhD

Committee Member

Harriet Lindsay, PhD

Committee Member

Cory Emal, PhD


Histone deacetylase inhibitors (HDIs) have found a wide variety of medicinal uses and are most noted for their specific apoptotic action towards cancer cells. Several hydroxamate HDIs have since been moved on to phase 1 and 2 clinical drug trials, with one having already been approved for treatment of advanced cutaneous T-cell lymphoma. Trichostatin A is one of the most potent known naturally-occurring inhibitors of histone deacetylase. Unfortunately for researchers, the syntheses that have been reported are both long and difficult, which leads to a low overall yield and therefore to a prohibitively expensive product, limiting its medicinal potential. This work builds on several previously published syntheses and shows a more efficient synthesis of Trichostatin A, which will make it more available for use in a variety of treatments.

Included in

Chemistry Commons